title: Secondary resistance to erlotinib: acquired T790M mutation and small-cell lung cancer transformation in the same patient.
authors.affiliation: Service de Pneumologie et Réanimation, Hôpital Tenon, Assistance Publique-Hôpitaux de Paris, Paris, France.
authors.forename: Vincent
authors.initials: V
authors.lastname: Fallet
authors.forename: Anne-Marie
authors.initials: AM
authors.lastname: Ruppert
authors.forename: Virginie
authors.initials: V
authors.lastname: Poulot
authors.forename: Roger
authors.initials: R
authors.lastname: Lacave
authors.forename: Laure
authors.initials: L
authors.lastname: Belmont
authors.forename: Martine
authors.initials: M
authors.lastname: Antoine
authors.forename: Jacques
authors.initials: J
authors.lastname: Cadranel
authors.forename: Marie
authors.initials: M
authors.lastname: Wislez
authors.forename: Armelle
authors.initials: A
authors.lastname: Lavolé
mesh_terms: D000328:Adult; D001706:Biopsy; D001999:Bronchoscopy; D002471:Cell Transformation, Neoplastic / Q000187:drug effects / Q000235:genetics* / Q000473:pathology; D004252:DNA Mutational Analysis; D003937:Diagnosis, Differential; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000235:genetics*; D000069347:Erlotinib Hydrochloride; D017809:Fatal Outcome; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use*; D017384:Sequence Deletion / Q000187:drug effects*; D055752:Small Cell Lung Carcinoma / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics; D014057:Tomography, X-Ray Computed
chemical_list: D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors